Similar articles

• Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Choueiri TK, et al. J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351323
• [Cutaneous side effects of sorafenib and sunitinib].

  Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Autier J, et al. Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Ann Dermatol Venereol. 2008. PMID: 18342102 Review. French. No abstract available.
• Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.

  Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F. Loriot Y, et al. Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22. Ann Oncol. 2008. PMID: 18723549 No abstract available.
• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. Patel TV, et al. J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12. J Natl Cancer Inst. 2008. PMID: 18270341 No abstract available.
• Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

  Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Torino F, et al. Thyroid. 2009 May;19(5):539-40. doi: 10.1089/thy.2008.0367. Thyroid. 2009. PMID: 19416001 No abstract available.